Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Outline of Final Research Achievements |
We have developed the malaria-vaccine platform using several kinds of modified baculovirus such as complement resistant baculovirus, dendritic targeting baculovirus, decoy-receptor expressing baculovirus, cytokine expressing baculovirus and shRNA expressing baculovirus. Among them, complement resistant baculovirus and cytokine expressing baculovirus worked very well in functional analyses. When immunized in mice, these baculovirus induced strong anti-malaria antibody response and conferred high protective efficacy against the infection with transgenic rodent malaria.
|